Baseline A1C Level Is the Key

4209

In people with higher A1Cs, rapid-actinginsulin analogs NovoLog (insulin aspart)and Humalog (insulin lispro) are moreeffective in achieving optimal blood glucosecontrol when administered with insulinpumps rather than via multiple daily insulininjections (MDII), according to University ofToronto researchers.

Data on 139 adults with type 1 diabeteswere evaluated from previous studies.The studies differed significantly in meanbaseline A1C levels (7.95%, 8.20% and9.27%).

“A model derived from these data predictsthat in a patient with a baseline A1C of10%, [rapid-acting insulin in pumps] wouldreduce the A1C by an additional 0.65%compared with MDII,” write the researchers.On the other hand, there would be no A1Cbenefit to using rapid-acting insulin inpumps, compared with MDII, if baselineA1Cs were 6.5%.

The researchers conclude that using fast-actinginsulin in pumps may be uniquelyadvantageous in adults with type 1 diabetesand poor blood glucose control.

Click here to view/write comments
Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.